These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
472 related articles for article (PubMed ID: 18547343)
1. Effect of metformin, orlistat and pioglitazone treatment on mean insulin resistance and its biological variability in polycystic ovary syndrome. Cho LW; Kilpatrick ES; Keevil BG; Coady AM; Atkin SL Clin Endocrinol (Oxf); 2009 Feb; 70(2):233-7. PubMed ID: 18547343 [TBL] [Abstract][Full Text] [Related]
2. Obesity, weight loss, and the polycystic ovary syndrome: effect of treatment with diet and orlistat for 24 weeks on insulin resistance and androgen levels. Panidis D; Farmakiotis D; Rousso D; Kourtis A; Katsikis I; Krassas G Fertil Steril; 2008 Apr; 89(4):899-906. PubMed ID: 17980364 [TBL] [Abstract][Full Text] [Related]
3. The effects of rosiglitazone and metformin on oxidative stress and homocysteine levels in lean patients with polycystic ovary syndrome. Yilmaz M; Bukan N; Ayvaz G; Karakoç A; Törüner F; Cakir N; Arslan M Hum Reprod; 2005 Dec; 20(12):3333-40. PubMed ID: 16123091 [TBL] [Abstract][Full Text] [Related]
4. Metformin versus rosiglitazone in the treatment of polycystic ovary syndrome. Mitkov M; Pehlivanov B; Terzieva D Eur J Obstet Gynecol Reprod Biol; 2006 May; 126(1):93-8. PubMed ID: 16360262 [TBL] [Abstract][Full Text] [Related]
5. Insulin sensitizing drugs increase the endogenous dopaminergic tone in obese insulin-resistant women with polycystic ovary syndrome. Ortega-González C; Cardoza L; Coutiño B; Hidalgo R; Arteaga-Troncoso G; Parra A J Endocrinol; 2005 Jan; 184(1):233-9. PubMed ID: 15642799 [TBL] [Abstract][Full Text] [Related]
6. Effect of long-term orlistat treatment on serum levels of advanced glycation end-products in women with polycystic ovary syndrome. Diamanti-Kandarakis E; Katsikis I; Piperi C; Alexandraki K; Panidis D Clin Endocrinol (Oxf); 2007 Jan; 66(1):103-9. PubMed ID: 17201808 [TBL] [Abstract][Full Text] [Related]
7. Effect of metformin and pioglitazone treatment on cardiovascular risk profile in polycystic ovary syndrome. Ziaee A; Oveisi S; Abedini A; Hashemipour S; Karimzadeh T; Ghorbani A Acta Med Indones; 2012 Jan; 44(1):16-22. PubMed ID: 22451180 [TBL] [Abstract][Full Text] [Related]
8. An observational study of reduction of insulin resistance and prevention of development of type 2 diabetes mellitus in women with polycystic ovary syndrome treated with metformin and diet. Glueck CJ; Goldenberg N; Sieve L; Wang P Metabolism; 2008 Jul; 57(7):954-60. PubMed ID: 18555837 [TBL] [Abstract][Full Text] [Related]
9. Nonobese women with polycystic ovary syndrome respond better than obese women to treatment with metformin. Maciel GA; Soares Júnior JM; Alves da Motta EL; Abi Haidar M; de Lima GR; Baracat EC Fertil Steril; 2004 Feb; 81(2):355-60. PubMed ID: 14967373 [TBL] [Abstract][Full Text] [Related]
10. [Metformin, an efficacious drug in the treatment of polycystic ovary syndrome]. Hahn S; Quadbeck B; Elsenbruch S; Gärtner R; Finke R; Mann K; Janssen OE Dtsch Med Wochenschr; 2004 May; 129(19):1059-64. PubMed ID: 15136950 [TBL] [Abstract][Full Text] [Related]
11. Metformin administration is more effective when non-obese patients with polycystic ovary syndrome show both hyperandrogenism and hyperinsulinemia. Genazzani AD; Lanzoni C; Ricchieri F; Baraldi E; Casarosa E; Jasonni VM Gynecol Endocrinol; 2007 Mar; 23(3):146-52. PubMed ID: 17454168 [TBL] [Abstract][Full Text] [Related]
12. Effect of orlistat or metformin in overweight and obese polycystic ovary syndrome patients with insulin resistance. Song J; Ruan X; Gu M; Wang L; Wang H; Mueck AO Gynecol Endocrinol; 2018 May; 34(5):413-417. PubMed ID: 29172796 [TBL] [Abstract][Full Text] [Related]
13. Responses of serum androgen and insulin resistance to metformin and pioglitazone in obese, insulin-resistant women with polycystic ovary syndrome. Ortega-González C; Luna S; Hernández L; Crespo G; Aguayo P; Arteaga-Troncoso G; Parra A J Clin Endocrinol Metab; 2005 Mar; 90(3):1360-5. PubMed ID: 15598674 [TBL] [Abstract][Full Text] [Related]
14. A randomized, 48-week, placebo-controlled trial of intensive lifestyle modification and/or metformin therapy in overweight women with polycystic ovary syndrome: a pilot study. Hoeger KM; Kochman L; Wixom N; Craig K; Miller RK; Guzick DS Fertil Steril; 2004 Aug; 82(2):421-9. PubMed ID: 15302293 [TBL] [Abstract][Full Text] [Related]
15. Effects of metformin treatment in women with polycystic ovary syndrome depends on insulin resistance. Nawrocka J; Starczewski A Gynecol Endocrinol; 2007 Apr; 23(4):231-7. PubMed ID: 17505944 [TBL] [Abstract][Full Text] [Related]
16. Acute effects of metformin therapy include improvement of insulin resistance and ovarian morphology. Bayrak A; Terbell H; Urwitz-Lane R; Mor E; Stanczyk FZ; Paulson RJ Fertil Steril; 2007 Apr; 87(4):870-5. PubMed ID: 17224152 [TBL] [Abstract][Full Text] [Related]
17. Combined lifestyle modification and metformin in obese patients with polycystic ovary syndrome. A randomized, placebo-controlled, double-blind multicentre study. Tang T; Glanville J; Hayden CJ; White D; Barth JH; Balen AH Hum Reprod; 2006 Jan; 21(1):80-9. PubMed ID: 16199429 [TBL] [Abstract][Full Text] [Related]
18. Predictive value of glucose-insulin ratio in PCOS and profile of women who will benefit from metformin therapy: obese, lean, hyper or normoinsulinemic? Onalan G; Goktolga U; Ceyhan T; Bagis T; Onalan R; Pabuçcu R Eur J Obstet Gynecol Reprod Biol; 2005 Dec; 123(2):204-11. PubMed ID: 16316811 [TBL] [Abstract][Full Text] [Related]
19. Reduction in hematocrit level after pioglitazone treatment is correlated with decreased plasma free testosterone level, not hemodilution, in women with polycystic ovary syndrome. Berria R; Gastaldelli A; Lucidi S; Belfort R; De Filippis E; Easton C; Brytzki R; Cusi K; Jovanovic L; DeFronzo R Clin Pharmacol Ther; 2006 Aug; 80(2):105-14. PubMed ID: 16890572 [TBL] [Abstract][Full Text] [Related]
20. Comparison of the effects of pioglitazone and metformin on insulin resistance and hormonal markers in patients with impaired glucose tolerance and early diabetes. Eguchi K; Tomizawa H; Ishikawa J; Hoshide S; Numao T; Fukuda T; Shimada K; Kario K Hypertens Res; 2007 Jan; 30(1):23-30. PubMed ID: 17460368 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]